Toolkit Developed for Diagnosis and Management of Menopause
|
By LabMedica International staff writers Posted on 04 Aug 2014 |
A simple toolkit designed to help general practitioners (GP) diagnose and manage menopause is now available free of charge.
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Created at Monash University (VIC, Australia), the "Practitioner Toolkit for Managing the Menopause" is the world’s first such kit, designed for GPs to use with women from the age of 40. The research team, led by Prof. Susan Davis, combined existing research on menopause, diagnostic algorithms, and extensive clinical experience to develop the diagnostic tool. It also helps the GP work through a patient’s medical history and risk factors to arrive at an optimal solution.
The toolkit fills the void of clear guidelines on diagnosis and management, equipping primary-care physicians, as well as nurses, with the fundamentals to provide more effective care for women. “There are many detailed guidelines available on menopause but the reality is that most GPs don’t have the time to work through a 40 page report [...] with a patient,” said Prof. Davis, “Based on feedback from patients and doctors we realized there’s widespread confusion." Also, "With many recent medical graduates receiving little training in this area, we realized there was a clear need for simple and practical guidelines,” she added.
Menopausal symptoms vary widely from none at all to debilitating, making a straightforward diagnosis difficult. "Every woman has her own individual experience of menopause and that sometimes makes it tricky to diagnose," said Prof. Davis. The kit includes a flow chart of standardized questions for doctors to ask in a routine consultation to help identify women who may be entering menopause. The kit also flags safety concerns, provides a list of hormone therapies approved by regulators in different countries, and lists non-hormonal therapies that have evidence to support their use. It also helps inform on benefits and risks of menopausal treatments. The kit is designed to work as well for a woman of age 41 in Madras as for one of age 48 in Manhattan, and the International Menopause Society is promoting its global use, stating that it is the first to present structured practical advice.
Jane Elliott, MD, said the toolkit was clear and accessible, making it ideal to use in GP consultations. Dr. Anna Fenton, a leading endocrinologist and president of the Australasian Menopause Society, also welcomed and recommended the toolkit: “In an area fraught with myths and misinformation, this toolkit provides concise and accurate information. The key messages are clear and the advice is practical and evidence-based,” said Dr. Fenton.
The paper on the kit was published online July 6, 2014, in the journal Climacteric.
Related Links:
Monash University
Menopause Toolkit for GPs
Latest Clinical Chem. News
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Channels
Molecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more








